Portfolio company Vicebio agreed to be acquired by Sanofi for up to $1.6 billion.
Vicebio is a biotech company focused on developing vaccines against life-threatening respiratory viral infections using its proprietary Molecular Clamp technology, which stabilizes viral proteins to enhance immune response
Vicebio is a biotech company focused on developing vaccines against life-threatening respiratory viral infections using its proprietary Molecular Clamp technology, which stabilizes viral proteins to enhance immune response.